Friends
The whole issue of late onset resistance to ibrutinib and other TKIs is a growing area of concern and research.
I will posting more on it in my blog ( bkoffman.blogspot.com ), but Dr. Furman gives us a nice starting perspective.
Stay strong
Brian
Admin: Links now working (HU will not cope with any characters adjacent to the end of the link and it is best to have spaces before and after links.)
Excellent video. Thank you. Made me feel very positive. I am about to start on Ibrutinib.
ASH 2015: Dr. John M Pagel on the Problems with Idelalisib as Frontline Therapy in CLLMy Take on 3 Interesting Papers on CLL from ASCO 2015BTK C481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic LeukemiaApproval of Imbruvica Frontline for 17p deleted CLL and Important TrialsASH 2014. Dr. Sharman discusses the biology of our CLL cells
